Đánh giá kết quả điều trị bước một bệnh nhân cao tuổi ung thư phổi không tế bào nhỏ giai đoạn muộn bằng phác đồ paclitaxel-carboplatin=Efficacy of paclitaxel-carboplatin regimen as the first-line treatment for elderly patients with advanced non-small cell lung cancer

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hùng Kiên Đỗ, Mai Linh Đỗ, Bảo Ngọc Hoàng, Khánh Toàn Nguyễn, Thị Thanh Thúy Nguyễn, Tuyết Mai Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.20-27

Bộ sưu tập: Báo, Tạp chí

ID: 478102

Thêm vào giỏ

Đánh giá đáp ứng điều trị bước một và một số tác dụng không mong muốn của phác đồ paclitaxel – carboplatin trên bệnh nhân cao tuổi ung thư phổi không tế bào nhỏ (UTPKTBN) giai đoạn muộn. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu, tiến hành trên bệnh nhân UTPKTBN giai đoạn IV, tuổi ≥ 60, chỉ số toàn trạng ECOG PS 0-2, được điều trị bước 1 bằng hóa chất paclitaxel – carboplatin tại Bệnh viện K và Bệnh viện Ung Bướu Nghệ An từ tháng 12/2016 đến tháng 6/2024. Kết quả: Có 165 bệnh nhân tham gia nghiên cứu, tuổi trung vị là 65 tuổi, trong đó có 137 bệnh nhân nam, chiếm 83%. Bệnh nhân có mô bệnh học ung thư biểu mô tuyến là 132 (80,0%) bệnh nhân. Có 65 (39,4%) bệnh nhân có bệnh lý đi kèm, 107 (64,8%) bệnh nhân có chỉ số toàn trạng ECOG 1 trước điều trị. Số bệnh nhân đạt đáp ứng khách quan là 101 (61,2%), tỉ lệ kiểm soát bệnh đạt 85,5% (141 bệnh nhân). Ung thư biểu mô không vảy có tỷ lệ đáp ứng cao hơn có ý nghĩa thống kê với nhóm BN ung thư biểu mô vảy (p<
0,05). Các tác dụng không mong muốn thường gặp gồm thiếu máu, độc tính thần kinh ngoại biên và tăng men gan, chủ yếu ở độ 1, 2. Kết luận: Phác đồ paclitaxel – carboplatin đem lại hiệu quả và an toàn trong điều trị bệnh nhân cao tuổi mắc UTPKTBN giai đoạn muộn.To evaluate the efficacy and safety of the combination regimen of paclitaxel plus carboplatin in untreated elderly patients with advanced non-small cell lung cancer (NSCLC). Materials and method: This retrospective study was conducted at the Vietnam National Cancer Hospital and Nghe An Oncology Hospital from December 2016 to Jun 2024. Treatmentnaïve patients with metastatic NSCLC with age ≥60 and ECOG PS ≤2 were eligible. Patients received at least 3 cycles of paclitaxel plus carboplatin. Results: 165 eligible patients were enrolled. Median age was 65.0±4.1 (range 60-75), 83% (n=137) of patients were male. Patients with adenocarcinoma accounted for 80% (n=132). Sixty-five (39.4%) patients had comorbidities, and patients with PS=1 before treatment accounted for 64.8% (n=107). Objective response rate was 63.0% (101 patients). Disease control rate was 85.5% (141 patients). Patients with squamous cell carcinoma (SCC) had statistically significantly higher response rate than those with non-SCC (p<
0.05) The most common side effects were anemia, peripheral neuropathy, and elevated liver enzymes, most of them were at grades 1 and 2. Conclusion: Paclitaxel-carboplatin regimen appeared to be effective and well tolerated for elderly patients with advanced NSCLC.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR